

**General Manager,  
Department of Corporate Services  
The Stock Exchange of India,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai**

**Dated: August 18th, 2008**

**SUBJECT: KENYA GMP ACCREDITATION FOR VENUS FACILITIES**

**Dear Sir,**

This is to inform you that the Company's manufacturing facilities have been accredited with Good Manufacturing Practices certification by the Pharmacy & Poisons Board, Ministry of Health, Kenya.

The Inspectorate of MoH, Kenya had conducted a detailed inspection of the manufacturing facilities at the Baddi Campus of the Company earlier this year and found them to be compliant of all quality standard requirements as per PPB and WHO-GMP norms.

This certification has opened the Kenyan markets for the Company products. The Company has filed 28 product dossiers for its range of Cephalosporin, Carbapenem and Oncology formulations for registration in Kenya, out of which 8 products have already been registered. The Company had tied up with one of the leading pharmaceutical distributor of Kenya and the first order for the territory has been successfully executed in the second quarter. The Company is expecting a healthy contribution to export sales from this territory.

**For VENUS REMEDIES LIMITED**

**(SONIA MALHOTRA)  
DGM (Corporate Planning & Communications)**

**Mr. Hari K.  
Asst. Vice President  
The National Stock Exchange of India Limited,  
Exchange Plaza, Bandra – Kurla Complex,  
Bandra (E)**

**Dated: August 18<sup>th</sup>, 2008**

**Mumbai-400 051**

**SUBJECT: KENYA GMP ACCREDITATION FOR VENUS FACILITIES**

**Dear Sir,**

This is to inform you that the Company's manufacturing facilities have been accredited with Good Manufacturing Practices certification by the Pharmacy & Poisons Board, Ministry of Health, Kenya.

The Inspectorate of MoH, Kenya had conducted a detailed inspection of the manufacturing facilities at the Baddi Campus of the Company earlier this year and found them to be compliant of all quality standard requirements as per PPB and WHO-GMP norms.

This certification has opened the Kenyan markets for the Company products. The Company has filed 28 product dossiers for its range of Cephalosporin, Carbapenem and Oncology formulations for registration in Kenya, out of which 8 products have already been registered. The Company had tied up with one of the leading pharmaceutical distributor of Kenya and the first order for the territory has been successfully executed in the second quarter. The Company is expecting a healthy contribution to export sales from this territory.

**For VENUS REMEDIES LIMITED**

**(SONIA MALHOTRA)  
DGM (Corporate Planning & Communications)  
Mr. Thomas DE CONINCK  
The Luxembourg Stock Exchange,  
Societe de la Bourse  
De Luxembourg  
Societe Anonyme  
RC Luxembourg B 6222**

**Dated: August 18th, 2008**

**SUBJECT: KENYA GMP ACCREDITATION FOR VENUS FACILITIES**

**Dear Sir,**

This is to inform you that the Company's manufacturing facilities have been accredited with Good Manufacturing Practices certification by the Pharmacy & Poisons Board, Ministry of Health, Kenya.

The Inspectorate of MoH, Kenya had conducted a detailed inspection of the manufacturing facilities at the Baddi Campus of the Company earlier this year and found them to be compliant of all quality standard requirements as per PPB and WHO-GMP norms.

This certification has opened the Kenyan markets for the Company products. The Company has filed 28 product dossiers for its range of Cephalosporin, Carbapenem and Oncology formulations for registration in Kenya, out of which 8 products have already been registered. The Company had tied up with one of the leading pharmaceutical distributor of Kenya and the first order for the territory has been successfully executed in the second quarter. The Company is expecting a healthy contribution to export sales from this territory.

For **VENUS REMEDIES LIMITED**

**(SONIA MALHOTRA)**  
**DGM (Corporate Planning & Communications)**